Tied with Cabenuva for second place was Amgen’s Lumakras, which was approved in 2021 for non-small cell lung cancer and boasted impressive therapeutic and R&D scores, but fell behind both ...
Two weeks after Amgen reported the top-line result of its CodeBreak-200 trial of Lumakras in lung cancer, the data has been presented in abstract form at ESMO, showing a 34% improvement in ...
Amgen is facing a slowdown in uptake of its first-to-market KRAS inhibitor Lumakras as a second-line therapy for KRAS-mutated non-small cell lung cancer (NSCLC), so is understandably excited by ...
With a sumptuous 240 Hz OLED display, a supremely slim and well-built chassis, and gaming performance to be proud of, I was absolutely smitten. You may like Time for me to tap the Asus G14 sign ...
Overall survival was statistically significantly improved in adults treated with tislelizumab/chemotherapy compared with placebo/chemotherapy. The Food and Drug ...
Issued on behalf of Oncolytics Biotech Inc. At the ASCO GI event, Oncolytics shared that in relapsed anal cancer, 4 out of 12 evaluable patients achieved a partial response for a response rate of ...
Like Jurassic Park, Matlock and Star Wars, the new Toyota Urban Cruiser is a reboot of something that’s come before. Where the previous Urban Cruiser was a fairly underwhelming SUV, however ...
Like Jurassic Park, Matlock and Star Wars, the new Toyota Urban Cruiser is a reboot of something that’s come before. Where the previous Urban Cruiser was a fairly underwhelming SUV, however ...
Hosted on MSN28d
Rare 240-year-old George Washington war letter comes up for saleThe letter, more than 240 years old, is written on both sides of a single sheet of paper roughly 8 by 12 inches. It is stained and discolored in many places and has what looks like a grimy ...
In January and February of this year, the US Food and Drug Administration granted approvals for Adcetris (brentuximab vedotin), Lumakras (sotorasib), Grafapex (treosulfan), Enhertu (fam ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results